Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Non-Current Liabilities (2017 - 2023)

Denali Therapeutics has reported Other Non-Current Liabilities over the past 7 years, most recently at $379000.0 for Q3 2023.

  • Quarterly Other Non-Current Liabilities changed 0.0% to $379000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $379000.0 through Sep 2023, changed 0.0% year-over-year, with the annual reading at $379000.0 for FY2022, 0.0% changed from the prior year.
  • Other Non-Current Liabilities was $379000.0 for Q3 2023 at Denali Therapeutics, roughly flat from $379000.0 in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $701000.0 in Q4 2020 and troughed at $379000.0 in Q4 2019.
  • The 5-year median for Other Non-Current Liabilities is $379000.0 (2019), against an average of $451894.7.
  • Year-over-year, Other Non-Current Liabilities skyrocketed 211.29% in 2019 and then plummeted 45.93% in 2021.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $379000.0 in 2019, then skyrocketed by 84.96% to $701000.0 in 2020, then plummeted by 45.93% to $379000.0 in 2021, then changed by 0.0% to $379000.0 in 2022, then changed by 0.0% to $379000.0 in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Other Non-Current Liabilities are $379000.0 (Q3 2023), $379000.0 (Q2 2023), and $379000.0 (Q1 2023).